ClinicalTrials.gg

Program

GHZ339

A development code.

In Novartis's pipeline, IL-13, IL18 inhibitor. Its studies are mostly in Dermatitis, Atopic, led by Novartis.

Furthest: phase 2, since Apr 25, 20251 company-led study, 1 open or runningNext primary completion: Nov 27, 2028 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Novartis11 open or runningphase 2since Apr 25, 2025Apr 25, 2025Nov 27, 2028phase 2 · NCT06947993
  • Named in Novartis’s own pipeline as GHZ339, phase 2, as of Nov 16, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Apr 25, 2025First study: phase 2 study in Dermatitis, AtopicFirst studyNCT06947993 · 224 planned · United States, Argentina, Canada and more

Ahead

  1. Nov 27, 2028Primary completion: phase 2 study in Dermatitis, AtopicNCT06947993

TargetBeta

“IL-13, IL18 inhibitor”the company's pipeline, read by Claude · source

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06947993Dermatitis, Atopic · United States, Argentina, Canada and more2RecruitingNov 27, 2028224

How it is read

Names in the registry

  • “GHZ339”, 1 entry

Codes read as this program: GHZ339.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.